Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
18 Years and older, Male and Female
Summary
The main purpose of this study is to see whether CDX-011 (glembatumumab vedotin, an
antibody-drug conjugate) is effective in treating patients who have advanced
Triple-Negative Breast Cancer (TNBC), and whose tumor cells make a protein called
glycoprotein NMB (gpNMB), which CDX-011 binds to. The study will also further
characterize the safety of CDX-011 treatment in this patient population.
Objectives
CDX-011 consists of an antibody attached to a drug, monomethyl auristatin E (MMAE), that
can kill cancer cells. The antibody delivers the drug to cancer cells by attaching to a
protein called glycoprotein NMB (gpNMB) that is expressed on the cancer cell. The MMAE is
then released inside of the cell, where it interferes with cell growth and may lead to
cell death.
This study will examine the efficacy and safety of CDX-011 in patients with advanced TNBC
that makes the gpNMB protein. The effect of CDX-011 will be compared to treatment with
capecitabine.
Eligible patients who enroll in the study will be randomly assigned (by chance) to
receive treatment with CDX-011 or with capecitabine. For every three patients enrolled,
two will receive CDX-011 and one will receive treatment with capecitabine. All patients
enrolled in the study will be closely monitored to determine if their cancer is
responding to treatment and for any side effects that may occur.
Eligibility
- Inclusion Criteria:
Among other criteria, patients must meet all of the following conditions to be eligible
for the study:
1. Diagnosed with metastatic (i.e., cancer that has spread) TNBC
- minimal or no expression of estrogen and progesterone receptors (ER/PR) <10% of
cells positive by immunohistochemistry
- HER 2 staining 0 or 1+ by IHC or copy number <4.0 signals/cell
2. Documented progression of disease based on radiographic, clinical or pathologic
assessment during or subsequent to the last anticancer regimen received.
3. Breast cancer tumor confirmed to express gpNMB. This will be determined by
submitting a tissue sample from the advanced (locally advanced/recurrent or
metastatic) disease setting to a central laboratory for analysis.
4. Received no more than two prior chemotherapy treatments for advanced (locally
advanced/recurrent or metastatic) breast cancer.
5. Prior chemotherapy treatment must have contained an anthracycline (e.g. doxorubicin
or Doxil) if clinically indicated and a taxane (eg: Taxol).
6. ECOG performance status of 0 - 1.
7. Adequate bone marrow, liver and renal function.
Exclusion:
Among other criteria, patients who meet any of the following conditions are NOT eligible
for the study:
1. Progression/recurrence of breast cancer during or within 3 months of completion of
neoadjuvant or adjuvant chemotherapy.
2. Ongoing neuropathy or other chemotherapy or radiation-related toxicities that are
moderate (Grade 2) or worse in severity.
3. Known brain metastases, unless previously treated and asymptomatic for 2 months and
not progressive in size or number for 2 months.
4. Significant cardiovascular disease.
5. Previously received capecitabine and discontinued due to progression or intolerance;
previously received CDX-011 or other MMAE containing agents.
6. Active systemic infection requiring treatment. Infection controlled by oral therapy
will not be exclusionary.
7. Chronic use of systemic corticosteroids.
Treatment Sites in Georgia
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials.